Skip to main content
Skip to main content
BMGL logo

Basel Medical Group Ltd (BMGL) Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

$4.58 -$0.20 (-4.18%) |Weak · 34
Basel Medical Group Ltd (BMGL) bottom line: signals are mixed — the Council read leans Split View (43/100) while the AI fundamental score is 34/100 (grade D); the two lenses disagree, so weigh the breakdown below. Strongest signal: Ray Dalio bullish · Biggest watch-out: Growth Durability weak.Educational signal, not a buy or sell recommendation. Compare sector peers → · Read the method →
MCap: $7.17M| Vol: 2.8K| 52-wk range: $4.17 – $25.80

Market cap $7.17M is the value of all shares combined.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Basel Medical Group Ltd (BMGL) trades at $4.58 with MoonshotScore 34/100 (Grade D). Basel Medical Group Ltd, incorporated in 2023 and based in Singapore, provides healthcare services. Market cap: $7.17M, Sector: Healthcare.

Price as of Sep 11, 2026 · Last analyzed: May 4, 2026
Basel Medical Group Ltd, incorporated in 2023 and based in Singapore, provides healthcare services. The company operates in medical specialists, medical supplies and equipment, medical technology, and pharmaceuticals.

Analyst Coverage for BMGL: BMGL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BMGL against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.

Watch the BMGL film Every key number, told as a short cinematic story — just press play. ~2 min
Council Score · Weighted Average of 3 Disciplines
Split View 43/100 · C

BMGL: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.

How is this calculated? →
MoonshotScore · Five-pillar engine · 34/100
Business Quality
Negative Is this a genuinely good business?
Financial Safety
Negative Could this blow up on me?
Valuation
Weak Am I paying a fair price?
Growth Durability
Negative Is the growth real and likely to last?
Momentum
Negative Is the market already moving on this?

Strongest side: Valuation (4/10, Weak). Weakest side: Growth Durability (1/10, Negative).

Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated)Ray Dalio
Favorable read
Simons-style lens (simulated)Jim Simons
Neutral read
Englander-style lens (simulated)Izzy Englander
Neutral read
Klarman-style lens (simulated)Seth Klarman
Favorable read
Moon AI lens (model)
Neutral read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Negative
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

Why this analysis is different

  • A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
  • An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
  • Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Basel Medical Group Ltd (BMGL) Healthcare & Pipeline Overview

CEOYen Feng Chhoa
Employees82
HeadquartersSingapore, SG
IPO Year2025

Basel Medical Group Ltd, established in 2023, offers diverse healthcare services, including medical specialists, supplies, technology, and pharmaceuticals. Based in Singapore, the company navigates the competitive healthcare landscape with a focus on innovation and integrated solutions, but currently faces challenges in profitability and market establishment.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 4, 2026

What Is the Investment Thesis for BMGL?

AI-written as of May 4, 2026 — figures and tone reflect the data available then, not today's score.

Basel Medical Group Ltd presents a high-risk, high-reward investment opportunity given its early stage and negative profit margin of -106.8%. The company's focus on diverse healthcare services, including medical specialists, supplies, technology, and pharmaceuticals, positions it to capitalize on the growing demand for integrated healthcare solutions in Singapore. A key value driver is the potential for revenue growth through strategic partnerships and expansion of its service offerings. However, the company's current financial performance and limited operating history pose significant risks. The negative profit margin indicates challenges in achieving profitability, and the company's small size (32 employees) may limit its ability to compete effectively with larger, more established players. The company's beta of -0.18 suggests low volatility relative to the market, but this may also reflect a lack of investor interest. Upcoming catalysts include potential partnerships with healthcare providers and the introduction of new medical technologies. Successful execution of these initiatives could drive revenue growth and improve profitability. However, failure to achieve these milestones could further erode investor confidence.

Based on FMP financials and quantitative analysis

BMGL Key Highlights

AI-written as of May 4, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $7.17M indicates a micro-cap company with high growth potential but also significant risk.

  • Negative profit margin of -106.8% highlights the company's current struggle to achieve profitability.
  • Gross margin of 77.7% suggests strong pricing power and efficient cost management in its core operations.
  • Beta of -0.18 indicates low volatility compared to the overall market, which may appeal to risk-averse investors.
  • Incorporated in 2023, the company is relatively new and still in the early stages of development and market penetration.

Who Are BMGL's Competitors?

BMGL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
CABR CABR $1.19 +4.39% $10.8M 345-pillar
MRAI Marpai, Inc. $3.75 -8.76% $94.9M 409-signal
CLOV Clover Health Investments, Corp. $4.71 +8.53% $2.44B 375-pillar
ALHC Alignment Healthcare, Inc. $12.54 -1.69% $2.60B 845-pillar
OSCR Oscar Health, Inc. $32.58 +2.58% $8.45B 955-pillar
MOH Molina Healthcare, Inc. $200.28 +3.17% $10.5B 715-pillar
CNC Centene Corporation $65.40 +2.09% $32.3B 715-pillar
HUM Humana Inc. $407.26 +1.63% $48.9B 535-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BMGL's Key Strengths?

Comprehensive healthcare service offerings.

  • Focus on innovation and technology.
  • Strategic partnerships with medical professionals.
  • Strong gross margin of 77.7%.

What Are BMGL's Weaknesses?

Negative profit margin of -106.8%.

  • Limited operating history.
  • Small size and limited resources.
  • Geographic concentration in Singapore.

What Could Drive BMGL Stock Higher?

Potential partnerships with hospitals and clinics to expand service offerings.

  • Introduction of new medical technologies to improve patient care.
  • Expansion of the medical specialist network to attract more patients.
  • Development of telehealth services to reach remote patients.

What Are the Key Risks for BMGL?

Intense competition from established healthcare providers.

  • Regulatory changes affecting the healthcare industry.
  • Economic downturn impacting healthcare spending.
  • Challenges in achieving profitability.
  • Limited operating history and small size.

What Are the Growth Opportunities for BMGL?

  • Expansion of Medical Specialist Network: Basel Medical Group can grow by expanding its network of medical specialists, offering a wider range of services to patients. The market for specialist medical services in Singapore is estimated at $2 billion annually, with a projected growth rate of 5% per year. By partnering with more specialists, Basel Medical Group can attract more patients and increase its revenue. The timeline for this expansion is ongoing, with new specialists being added as opportunities arise. A competitive advantage lies in offering integrated care through a diverse network.
  • Adoption of Advanced Medical Technology: Investing in and integrating advanced medical technology can significantly enhance Basel Medical Group's service offerings and attract a tech-savvy patient base. By adopting technologies like AI-powered diagnostics and robotic surgery, Basel Medical Group can improve patient outcomes and efficiency. The timeline for implementing these technologies is 2-3 years, requiring significant investment and training. A competitive advantage lies in being an early adopter of cutting-edge technology.
  • Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with hospitals, clinics, and other healthcare providers can expand Basel Medical Group's reach and access to patients. The market for healthcare partnerships in Singapore is growing, with providers seeking to offer more comprehensive services. By partnering with established healthcare institutions, Basel Medical Group can gain access to a larger patient base and improve its brand recognition. The timeline for establishing these partnerships is ongoing, with negotiations and agreements being pursued continuously. A competitive advantage lies in creating mutually beneficial relationships with key players in the healthcare ecosystem.
  • Development of Telehealth Services: Offering telehealth services can expand Basel Medical Group's reach to patients in remote areas and those who prefer virtual consultations. The global telehealth market is projected to reach $175 billion by 2026. By developing a user-friendly telehealth platform, Basel Medical Group can attract new patients and increase its revenue. The timeline for developing and launching a telehealth platform is 1-2 years, requiring investment in technology and marketing. A competitive advantage lies in providing convenient and accessible healthcare services.
  • Expansion into Medical Supplies and Equipment Distribution: Basel Medical Group can diversify its revenue streams by expanding into the distribution of medical supplies and equipment. The market for medical supplies and equipment in Singapore is estimated at $1 billion annually. By becoming a distributor, Basel Medical Group can leverage its existing relationships with healthcare providers and generate additional revenue. The timeline for establishing a distribution network is 2-3 years, requiring investment in logistics and inventory management. A competitive advantage lies in offering a comprehensive range of healthcare solutions.

What Are BMGL's Competitive Advantages?

  • Integrated Service Offerings: Combining medical specialists, supplies, technology, and pharmaceuticals provides a comprehensive solution that is difficult for competitors to replicate.
  • Established Partnerships: Strong relationships with medical professionals and healthcare providers create a network effect that enhances the company's reach and reputation.
  • Focus on Innovation: Continuous investment in new technologies and services differentiates the company from competitors and attracts a tech-savvy patient base.

What Does BMGL Do?

Basel Medical Group Ltd was founded in 2023 in Singapore with the vision of providing comprehensive healthcare solutions. The company's services span several key areas within the healthcare sector, including medical specialists, medical supplies and equipment, medical technology, and pharmaceuticals. Basel Medical Group aims to integrate these services to offer a holistic approach to healthcare, targeting both individual patients and healthcare institutions. Since its inception, Basel Medical Group has focused on establishing its presence in the Singaporean market. The company's strategy involves building partnerships with local medical professionals and healthcare providers to expand its service offerings and reach. While still in its early stages, Basel Medical Group is working to develop a reputation for quality and innovation in the healthcare sector. The company's current market position is that of a relatively new entrant seeking to gain traction in a competitive environment. Its success will depend on its ability to differentiate itself through superior service, innovative technologies, and effective partnerships. Basel Medical Group's geographic reach is currently limited to Singapore, but the company may have plans for future expansion into other Southeast Asian markets.

What Products and Services Does BMGL Offer?

  • Provides medical specialist services across various disciplines.
  • Supplies medical equipment to healthcare facilities.
  • Offers medical technology solutions to improve patient care.
  • Distributes pharmaceutical products to pharmacies and hospitals.
  • Integrates healthcare services to provide comprehensive solutions.
  • Partners with medical professionals to expand service offerings.
  • Focuses on innovation in the healthcare sector.

How Does BMGL Make Money?

  • Generates revenue through fees for medical specialist services.
  • Earns income from the sale of medical supplies and equipment.
  • Profits from the distribution of pharmaceutical products.
  • Forms strategic alliances with healthcare providers to expand market reach.

What Industry Does BMGL Operate In?

Basel Medical Group Ltd operates within the healthcare industry, specifically in the medical and healthcare plans segment. This industry is characterized by increasing demand for healthcare services, driven by an aging population and rising prevalence of chronic diseases. The market is highly competitive, with established players and new entrants vying for market share. Basel Medical Group's focus on integrated healthcare solutions aligns with the industry trend towards value-based care and personalized medicine. The company's success will depend on its ability to differentiate itself through innovation, quality, and cost-effectiveness. The healthcare market in Singapore is expected to grow at a steady pace, providing opportunities for companies like Basel Medical Group to expand their reach and service offerings.

Who Are BMGL's Key Customers?

  • Individual patients seeking specialized medical care.
  • Hospitals and clinics requiring medical supplies and equipment.
  • Pharmacies needing pharmaceutical products for dispensing.
  • Healthcare institutions looking for integrated healthcare solutions.
Model self-rating on this text: 66% (not a measure of the evidence) Updated: May 4, 2026

Research confidence

Medium 60/100

Enough evidence to be useful, with gaps worth knowing about.

  • Scored on 82% of our measures
  • Price is current
  • No filing on record
  • No analyst coverage

Why 34?

Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.

What is helping

  • +0.37 Enterprise value vs sales (Valuation)
  • +0.17 Volatility vs the market (Financial Strength)
  • +0.14 Price to book (Valuation)

What is holding it back

  • -0.78 Net margin (Business Quality)
  • -0.60 Debt to equity (Financial Strength)
  • -0.54 Earnings yield (Valuation)

Risk penalties applied

  • -1.21 Loss-making and burning cash

Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →

MoonshotScore History

Recorded daily since 2026-08-23 · 19 snapshots

2026-08-23 51
2026-08-26 51
2026-08-29 51
2026-09-01 36
2026-09-04 36
2026-09-07 34
2026-09-10 34

What changed?

The grade moved from 51 to 34 (-17).

Over the same 18 days the stock moved -11.7%.

Company Profile

Basel Medical Group Ltd operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Singapore, SG. The company is led by CEO Yen Feng Chhoa. BMGL has traded publicly since 2025.

BMGL Valuation & Market Position

With a $7.17M market cap, Basel Medical Group Ltd sits in the micro-cap segment of the market. Relative to its peer group, BMGL's quantitative score of 34/100 is below the peer average of 61/100.

Key Financial Metrics

Return on assets is -71.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -30.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.23 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -84.7%, the inverse of the P/E and a quick read on earnings relative to price.

BMGL Financials

Fundamental Snapshot

Revenue Growth (FY)
+12.6%
Free Cash Flow Growth (FY)
-275.9%
Return on Equity (TTM)
-194.6%
Current Ratio
1.2

Based on FMP financials and quantitative analysis · FY 2024

Bull Case vs Bear Case

Bull Case

  • Comprehensive healthcare service offerings.
  • Focus on innovation and technology.
  • Strategic partnerships with medical professionals.
  • Strong gross margin of 77.7%.

Bear Case

  • Negative profit margin of -106.8%.
  • Limited operating history.
  • Small size and limited resources.
  • Geographic concentration in Singapore.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · September 2026

BMGL Latest News

BMGL Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BMGL.

Price Targets

Wall Street price target analysis for BMGL.

BMGL MoonshotScore

34/100

What does this score mean?

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. BMGL scores 34/100 (Grade D): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Leadership: Yen Feng Chhoa

Unknown

Yen Feng Chhoa is the managing director of Basel Medical Group Ltd, overseeing the operations of 32 employees. As the leader of a relatively new company incorporated in 2023, Yen Feng Chhoa is responsible for guiding the company's strategic direction and growth in the competitive healthcare market.

Track Record: Given the company's recent incorporation in 2023, Yen Feng Chhoa's track record is still developing. Key milestones under their leadership include establishing the company's presence in the Singaporean market and building partnerships with local medical professionals. The company's future success will depend on Yen Feng Chhoa's ability to execute the company's strategic plan and achieve profitability.

BMGL Healthcare Stock FAQ

What does the AI Score mean for BMGL?

BMGL holds an AI Score of 34/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Basel Medical Group Ltd, incorporated in 2023 and based in Singapore, provides healthcare services.

Is BMGL a good stock?

Stock Expert AI does not rate BMGL buy, sell or hold. Basel Medical Group Ltd carries a MoonshotScore of 34/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.

What do analysts say about BMGL stock?

As of 2026-05-04, analyst coverage of Basel Medical Group Ltd Ordinary Shares (BMGL) is limited due to its small market capitalization and recent incorporation. Key valuation metrics, such as price-to-earnings ratio, are not applicable due to the company's negative profit margin.

What are the key factors to evaluate for BMGL?

Basel Medical Group Ltd (BMGL) holds a MoonshotScore of 34/100 (low). A key value driver is the potential for revenue growth through strategic partnerships and expansion of its service offerings. Not financial advice.

How frequently does BMGL data refresh on this page?

BMGL's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven BMGL's recent stock price performance?

Basel Medical Group Ltd (BMGL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive healthcare service offerings. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider BMGL overvalued or undervalued right now?

Basel Medical Group Ltd (BMGL) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of BMGL?

Yes, most major brokerages offer fractional shares of Basel Medical Group Ltd (BMGL) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track BMGL's earnings and financial reports?

Basel Medical Group Ltd (BMGL) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BMGL earnings announcements.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated MoonshotScore as of
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited financial data available due to the company's recent incorporation.
  • Analyst coverage is limited due to the company's small market capitalization.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

More Stocks We Cover